100–300 mcg of each peptide per injection, 1–2 times daily (literature-based investigational use)
Frequency
1–2 times daily (fasted administration described in research contexts)
Key Safety Warning
Not FDA-approved. Contraindicated in active malignancy, pituitary tumors, and pregnancy. Combination therapy may increase IGF-1 levels. Food intake, particularly elevated glucose, may significantly blunt GH response.
Mechanism of Action (Educational)
CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that stimulates the anterior pituitary to release growth hormone in a physiologic pulsatile pattern. Ipamorelin is a selective ghrelin receptor (GHSR-1a) agonist that stimulates pulsatile GH release without significant stimulation of cortisol or prolactin. When administered together, the combination provides synergistic stimulation of endogenous GH through complementary hypothalamic–pituitary pathways. Growth hormone pulses are typically observed within 15–30 minutes following administration.
Indications (Investigational / Literature)
Growth hormone optimization research
IGF-1 modulation investigations
Body composition studies
Recovery and sleep-related research
Administration (Literature)
Parameter
Details
Route
Subcutaneous
Frequency
1–2 times daily
Injection Sites
Abdomen, thigh, upper arm (rotate sites)
Timing
Typically administered in a fasted state; bedtime commonly described in research contexts
Pharmacokinetics (Literature)
CJC-1295 without DAC has an approximate half-life of ~30 minutes. Ipamorelin has an approximate half-life of ~2 hours. GH release is generally observed within 15–30 minutes following administration. High glucose intake may blunt GH response. Glucocorticoids may inhibit GHRH-mediated GH secretion.
Titration Schedule (Literature-Based Example)
Weeks 1–2
100 mcg / 100 mcg at bedtime
Weeks 3–4
200 mcg / 200 mcg 1–2 times daily
Week 5+
200–300 mcg of each peptide per injection
Escalation is typically guided by IGF-1 response and tolerability.
For educational standardization purposes, concentration may be normalized so that 0.10 mL (10 insulin units) = 100 mcg of each peptide.
Parameter
Value
Target Concentration
1 mg/mL each peptide (1000 mcg/mL)
Unit Conversion
0.10 mL (10 units) = 100 mcg / 100 mcg
Example (5 mg / 5 mg vial)
Reconstitute with 5.0 mL bacteriostatic water → 1 mg/mL each
Stability
Up to 28 days refrigerated (2–8°C; varies by formulation)
Conversion Reference
10 units
100 mcg / 100 mcg
20 units
200 mcg / 200 mcg
30 units
300 mcg / 300 mcg
This section is provided strictly for arithmetic illustration and does not constitute dosing guidance.
Mathematical Calculation Tool
The calculator below allows mathematical concentration and volume calculations using variable vial strengths and reconstitution volumes. This tool is provided strictly for arithmetic reference.
Peptide Reconstitution Calculator
For Educational & Professional Reference Only
⚠️ This is a mathematical reference tool only. No medical or dosing advice is provided.
Calculated Results
Concentration
mg/mL
( mcg/mL)
Volume mL
U-100 Units units
U-100 Insulin Syringe
0
10
20
30
40
50
60
70
80
90
100
Plunger edge aligns to exact unit mark (1 unit = 0.01 mL).
Safety & Contraindications (Summary)
Contraindications
Active malignancy
Pituitary tumors
Diabetic retinopathy
Pregnancy or breastfeeding
Drug Interactions
High glucose intake may blunt GH response
Glucocorticoids may reduce GH release
Adverse Events
Flushing
Headache
Dizziness
Tingling sensations
Transient increased hunger
Higher-Dose Risks
Water retention
Joint discomfort
Monitoring (Literature)
IGF-1 levels
Fasting glucose
Body composition changes
Clinical tolerability
Disclaimer
CJC-1295 and Ipamorelin are investigational peptides and are not FDA-approved for anti-aging or body composition purposes. This content is provided strictly as a pharmacologic and mathematical reference for educational and professional use. It does not constitute medical advice or prescribing guidance.
